Skip to content

Golimumab

Tumor Necrosis Factor Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: CNTO 148, CNTO-148, simponi

EMA approvedFDA approvedATC L04AB06

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Golimumab is a drug in the Tumor Necrosis Factor Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2009. Its mechanism of action is classified as Tumor Necrosis Factor Receptor Blocking Activity. DrugCentral lists 1 molecular target, including TNF. Recorded indications include Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis and Polyarticular juvenile idiopathic arthritis.

  • Drug class: Tumor Necrosis Factor Blocker.
  • Mechanism of action: Tumor Necrosis Factor Receptor Blocking Activity.
  • Molecular targets: TNF (1 listed in DrugCentral).
  • Indications: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Polyarticular juvenile idiopathic arthritis and Psoriasis with arthropathy and others.
  • ATC code: L04AB06 (Tumor necrosis factor alpha (TNF-alpha) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

  • Ankylosing spondylitis
  • Juvenile idiopathic arthritis
  • Nonradiographic axial spondyloarthritis
  • Polyarticular juvenile idiopathic arthritis
  • Psoriasis with arthropathy
  • Rheumatoid arthritis
  • Ulcerative colitis

Mechanism & targets

Mechanism of action (MoA)Tumor Necrosis Factor Receptor Blocking Activity
Established pharmacologic classTumor Necrosis Factor Blocker

Molecular targets (1)

TargetGeneActionActivity
Tumor necrosis factorTNFother—

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2009-10-01EMA——
2009-04-24FDA—CENTOCOR ORTHO BIOTECH INC

ATC classification

ATC codeTherapeutic hierarchy
L04AB06ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Pemphigus5337.6
Contraindicated product administered5192.3
Glossodynia5191.6
Systemic lupus erythematosus4973.9
Hand deformity4441.5
Synovitis4080.7
Alopecia3953.8
Arthropathy3923.7
Swelling3872.5
Wound3762.7
Joint swelling3750.2
Therapeutic product effect decreased3591.7

Chemical structure

Molecular formula—
Molecular weight—
CAS number476181-74-5
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Golimumab used for?

DrugCentral lists the following indications for Golimumab: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Polyarticular juvenile idiopathic arthritis, Psoriasis with arthropathy, Rheumatoid arthritis and Ulcerative colitis.

How does Golimumab work?

Golimumab is classified as Tumor Necrosis Factor Receptor Blocking Activity; its molecular targets in DrugCentral include TNF.

When was Golimumab first approved?

Golimumab was first approved by the FDA in 2009.

What drug class does Golimumab belong to?

Golimumab is in the Tumor Necrosis Factor Blocker class.

Browse: all drugs starting with G · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2009-04-24
AgencyFDA
Targets1
Indications7
Formula—
DrugCentral ID4967
Interactive profile